Capitol Hill Briefs
This article was originally published in The Gray Sheet
Two House bills that seem simple on the surface – one on protecting “good Samaritans” from liability when they use automatic external defibrillators on cardiac arrest victims; one targeting public educational programs for cell-free DNA prenatal screening – sparked debate at a Dec. 9 Energy and Commerce Committee hearing. Also: legislators are attempting to insert device tax repeal provisions into must-pass 2016 agency funding and tax-extender bills.
You may also be interested in...
CMS Deputy Administrator for Innovation and Quality Patrick Conway and FDA Device Center Director Jeffrey Shuren told a House subcommittee that legislators’ efforts to replace FDA’s proposed laboratory-developed test framework would lead to duplicative, time-consuming, expensive regulation, and could only result in ineffective and delayed diagnostics that might harm patients.
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.